Nine mu g intradermal influenza vaccine and 15 mu g intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults

摘要

Intanza (R) 9 mu g (Sanofi Pasteur), a trivalent split-virion vaccine administered by intradermal (ID) injection, was approved in Europe in 2009 for the prevention of seasonal influenza in adults 18 to 59 years. Here, we examined the immune responses induced in adults by the ID 9 mu g vaccine and the standard trivalent intramuscular (IM) vaccine (Vaxigrip (R) 15 mu g, Sanofi Pasteur). This trial was a randomized, controlled, single-center, open-label study in healthy adults 18 to 40 years of age during the 2007/8 influenza season. Subjects received a single vaccination with the ID 9 mu g (n = 38) or IM 15 mu g (n = 42) vaccine. Serum, saliva, and peripheral blood mononuclear cells were collected up to 180 days post-vaccination.